ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Clinical trial NCT07089641 · RECRUITING

Trial details

NCT number: NCT07089641
Sponsor: Jonsson Comprehensive Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Glioblastoma Glioblastoma, IDH-Wildtype Gliosarcoma Recurrent Glioblastoma, IDH-Wildtype Recurrent Gliosarcoma Resectable Glioblastoma

Start date: 2025-07-28
Primary completion: 2027-07-30
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.